circRNA meets gene amplification

circRNA meets gene amplification

Nicholas Manguso1, Armando E. Giuliano1,2, Hisashi Tanaka1,2

1Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA2Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA

Correspondence to: Hisashi Tanaka, MD, PhD. Associate Professor, Cedars-Sinai Medical Center, Department of Surgery, 8700 Beverly Blvd, Davis Building 2058, Los Angeles, CA 90048, USA. Email:

Comment on: Qiu M, Xia W, Chen R, et al. The Circular RNA circPRKCI Promotes Tumor Growth in Lung Adenocarcinoma. Cancer Res 2018;78:2839-51.

Received: 04 June 2018; Accepted: 27 June 2018; Published: 28 June 2018.

doi: 10.21037/ncri.2018.06.04

Lung cancer remains the most common cause of cancer related death among both males and females globally accounting for 1.69 million deaths in 2015 (1). Of the different types of lung cancer, lung adenocarcinoma (LAC) is the most common (2). Given the prevalence and lethality of lung cancer the need to elucidate the mechanisms of this disease and to develop novel therapeutic targets remains paramount. The understanding of the biology and genetics of LAC is essential to learning more about this disease.

The recognition of copy number variation (CNV) across the genome, leading to gain (amplification) and loss (deletion) of function of DNA segments has been well studied. These CNVs have been found to play a role in the tumorigenesis of a number of cancers including lung cancer (3). Most previous research has investigated the gain of oncogenic proteins, such as MYC (4), or the loss of tumor suppressors, such as PTEN (5), however, oncogenic proteins represent only a small portion of the genomic regions exhibiting CNV. While protein coding genes occupy less than 5% of the genome, more than 50% of the genome is transcribed (6). The non-coding portion of the transcriptome has been gaining increasing attention as numerous studies have implicated non-coding RNA in the development and regulation of cancer (5), and, as the majority of the transcriptome, non-coding RNAs represent a tremendous area of unexplored opportunities.

In addition to the classical small noncoding RNA species that are essential for RNA metabolisms (e.g., small nuclear and nucleolar RNA), recent advances in genomic analysis have to led to further discoveries of a variety of non-coding RNA: long non-coding RNA (lncRNA), microRNA (miRNA), enhancer RNA (eRNA) and circular RNA (circRNA) (7,8). Specifically, circRNAs are naturally occurring non-coding RNAs generated possibly through exon circularization from precursor RNAs and are mainly found in the cytoplasm. They have been shown to modulate a number of biological processes such as cell proliferation and cell cycle regulation (9). circRNAs have also been identified in cancer cells, such as circPVT1 in gastric cancer (10) and circMTO1 in hepatocellular cancer (11). The most common mechanism by which these circRNAs regulate cell function is through microRNA (miRNA) sponging. miRNA plays a significant role in the regulation of gene expression through binding to mRNA and causing either degradation or inhibition of that particular mRNA. A single miRNA can have multiple targets across the transcriptome and a single mRNA can be the target of numerous miRNAs and vice versa (12). As such, the abundance of miRNA is an important part of post-transcriptional regulation. One mechanism to disturb the regulation is through miRNA sponging where different forms of RNAs can bind to the complementary sequence of a miRNA to “absorb” miRNA and prevent the binding of the miRNA to the target mRNA. Such miRNA sponging function has been demonstrated first for the circRNAs from CDR1 and SRY loci (13). Since then, the miRNA sponge by circRNA has been shown to regulate pluripotency, function, proliferation and apoptosis in cells (13-16). miRNA sponging has also been shown to function in several cancers such as: gastric (10), hepatocellular (11) and colon cancer (17). However, the presence and/or function of circRNAs in LAC is largely unknown. Furthermore, circRNAs arising from CNV regions have not been identified before. The recent study by Qiu et al. is the first to report the significance of circPRKCI in LAC (18). The authors eloquently identified circPRKCI as a prognosticator of LAC and elucidated the mechanism of circPRKCI, providing a potential treatment target for this lethal disease.

They initially cross referenced tumor-specific circRNAs from 5 LAC patients with common CNVs in LAC from TCGA data and found the circRNA associated with the gene protein kinase C iota (PRKCI) (18). PRKCI is located within the 3 Mb region of 3q26.2 that is frequently amplified in lung cancer (3,19). PRKCI and SOX2 are leading candidates of the target genes within the 3q26.2 amplicons and have been shown to promote the stem-like phenotype in squamous cell carcinoma of the lung (20). However, it is possible that non-coding RNA within the amplicon can also be a target in LAC. Based on the integrated screening of circRNA expression and CNV, the authors hypothesized that circPRKCI arising from the PRKCI gene may play a role in lung cancer and further characterized circPRKCI.

In addition to identifying the presence of circPRKCI, the authors correlated circPRKCI levels and outcomes in LAC. circPRKCI was found to be overexpressed in tumor tissue compared to normal tissue with an average fold change of 6.89 (18). They further found circPRKCI expression was higher in larger tumors, and those with stage II-III tumors had higher circPRKCI expression than those that were stage I. Furthermore, they verified this finding using chromogenic in-situ hybridization (CISH) which showed that higher CISH expression of circPRKCI correlated with size and TNM stage (18). While this was an important finding, most interesting was that patients with higher CISH expression in their LAC tumors had a shorter overall survival and on multivariate analysis circPRKCI expression level is an independent poor prognostic factor (hazard ratio 2.66) (18). Prognostic factors are important in determining treatment algorithms and surveillance of patients, however, a prognostic characteristic holds much more importance when the characteristic can be acted on to alter the prognosis of the patient. Previous studies have identified circRNAs as prognostic biomarkers in cancer (10), including lung cancer (21). The importance of circRNAs as prognostic biomarkers in cancer cannot be understated as they represent not just a prognostic characteristic but also a potential therapeutic target.

In order to identify whether circPRKC has more than just prognostic value, Qiu et al. further investigated the mechanism by which circPRKCI may actually influence tumor characteristics, and how targeting this circular RNA may be used to improve outcomes. LAC often presents with advanced disease that requires treatment beyond just surgical resection, as such, improved treatments in order to curtail the effects of this terrible disease continues to be important.

Qiu and colleagues found that circPRKCI contributes to cell growth and migration in vitro. They clearly showed that knockdown of circPRKCI significantly impaired cell proliferation while overexpression promoted proliferation (18). Further, knockdown of circPRKCI arrested cells in G1 but did not affect cell apoptosis. When examining the invasion of these LAC cell lines they found that si-circPRKCI treatment significantly impaired the invasion capacity of the cells (18). Overall, these findings suggest that circPRKCI promotes cell proliferation and migration of LAC cells. The implication of these results further suggests the importance of circPRKCI in maintaining the malignant environment of LAC, and again, suggests a possible target for modifying the biology of LAC tumors.

The authors determined that circPRKCI was predominantly present in the cytoplasm of the cell (18). Based on this finding they hypothesized that circPRKCI may be functioning as a miRNA sponge. miRNA bound to circRNA can form a complex with Argonaut 2 (Ago2). Qiu et al. was able to show that circPRKCI was pulled down with Ago2, and among putative target microRNA, miR-589 and miR-545 bound to circPRKCI in LAC cells (18). The direct interaction of circPRKCI and miR-545 and miR-589 was further established by mutating the binding sites to miR-545 and miR-589 (18). Additionally, silencing of circPRKCI did not actually effect the expression of miR-545 or miR-589, and transfection with miR-545 and miR-589 mimics did not affect expression of circPRKCI (18). Thus, circPRKCI likely acts as a sponge but does not downregulate the expression of these miRNAs. As the mechanism of these two miRNAs are relatively unknown, the authors further investigated the biologic function of miR-545 and miR-589 finding that they inhibited cell proliferation and induced G1 arrest in vitro (18). These findings further support the hypothesis that absorbing miR-589 and miR-545 by circPRKCI’s sponging function could promote tumor cell proliferation by inhibiting these two microRNA in LAC cells.

Next, the authors were able to determine the mRNA target of miR-545 and miR-589 that can be rescued from degradation by circPRKCI. By either silencing of circPRKCI or transfection with miR-545 or miR-589 mimics they identified the E2F7 gene was significantly downregulated (18). E2F7 is a transcription factor that plays an essential role in the regulation of the cell cycle. This transcription factor negatively regulates cyclin-dependent kinase inhibitor p21 leading to upregulation of Cyclin D1 (22) and promote cancer cell proliferation (23). miR-545 and miR-589 mimics indeed led to the upregulation of p21 and downregulation of cyclin D1 (18). Silencing of E2F7 inhibited LAC cell proliferation and led to G1 arrest. Modulation of circPRKCI recapitulated these phenotypes (18). While silencing of circPRKCI led to upregulation of p21 and downregulation of cyclin D1, overexpression of circPRKCI increased E2F7 protein levels and promoted cell proliferation (18).

The above findings delicately show that in vitro circPRKCI functions by acting as a miRNA sponge to miR-545 and miR-589 thereby increasing expression of E2F7. With this strong evidence in vitro, Qiu et al. further investigated this mechanism in vivo. First using a xenograft tumor model and patient-derived tumor primary cultures, they found that downregulation of circPRKCI led to smaller tumors (18). This is consistent with their earlier finding that patients with lower circPRKCI expression in their tumors had lower T stage tumors. Further, the cells collected from si-circPRKCI injected mice showed lower E2F7, lower Cyclin D1 and higher p21 expression, again consistent with findings in vitro (18). Lastly, circPRKCI inhibition on the effectiveness of already developed EGFR tyrosine kinase inhibitors was assessed using proliferation assays in vitro of EGFR mutant LAC cells. As expected, both the EGFR tyrosine kinase inhibitor and si-circPRKCI treatments inhibited cell growth, but combined treatment with both an EGFR directed drug and si-circPRKCI had a stronger inhibition, indicating that circPRKCI promotes tumor growth independently from EGFR signaling (18). These findings validate the previous in vitro results using an in vivo model, and identify a potential therapeutic target for patients with LAC both as a standalone treatment or in conjunction with already known targeted therapies.

circRNAs are unique non-coding RNA structures that predominantly occupy the cytoplasm and function as miRNA sponges, thereby regulating transcription and affecting cell function. Qiu et al. have identified a novel circRNA, circPRKCI, that is derived from a recurrent CNV locus in lung adenocarcinoma. The 3q26.2 amplicon harbors two candidate targets PRKCI and SOX2 (20) and the authors have shown that circPRKCI may not function through SOX2 signaling (18). In this regard, it would be interesting to see whether the poor prognosis of patients with high level of circPRKCI expression is independent of the amplification of 3q26.2 in the future study. Another interesting question is how circRNAs are generated from amplified genomic regions. A large number of circRNAs have been identified in the human genome, and back-splicing of the transcript from the native gene locus is considered to be a dominant mechanism for producing circRNA. However, cancer genomes, in particular genomic amplification consist of complex rearrangements (24). Considering the efficient generation of circPRKCI under the strong promoter in the transgene system (Figure 3A) (18), it is plausible to envision a similar situation can be created somatically by rearrangements in the cancer genome and continuously produce circRNAs that promotes tumor growth.

Through elucidating the presence of and mechanism by which circPRKCI functions in lung adenocarcinoma, the authors have not only identified a biomarker for lung adenocarcinoma but they have also awoken the opportunity for the discovery of other circRNAs across the transcriptome that may be derived from CNVs with similar prognostic and therapeutic potential. Additionally, in a focused setting this has tremendous implications for the future treatment of LAC. The ability to combine targeted therapies with independent targets may improve anti-tumor efficacy and potentially limit medication toxicity, often experienced with various chemotherapy regimens. Further, from a biologic standpoint, the ongoing advances in understanding how circRNAs are involved in cancer development, proliferation, and aggressiveness through their post-transcriptional regulation of gene expression provides great opportunity and promise for future treatment advances and therapeutic development across many cancer types.


Funding: This work is supported by the National Cancer Institute (R03CA188111) and Cedars-Sinai Medical Center (to H.T.); the Margie and Robert E. Petersen Foundation, the Fashion Footwear Charitable Foundation of New York, Inc., the Avon Foundation, and Associates for Breast and Prostate Cancer Studies (to A.E.G.).


Provenance and Peer Review: This article was commissioned and reviewed by the Section Editor Dr. Rongrong Gao (Department of Cardiology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China).

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See:


  1. World Health Organization Cancer Fact Sheet. 2018. Available online:
  2. Fry WA, Phillips JL, Menck HR. Ten-year survey of lung cancer treatment and survival in hospitals in the United States: a national cancer data base report. Cancer 1999;86:1867-76. [Crossref] [PubMed]
  3. Network CGAR. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012;489:519-25. [Crossref] [PubMed]
  4. Zhang X, Choi PS, Francis JM, et al. Identification of focally amplified lineage-specific super-enhancers in human epithelial cancers. Nat Genet 2016;48:176-82. [Crossref] [PubMed]
  5. Zhou CC, Yang F, Yuan SX, et al. Systemic genome screening identifies the outcome associated focal loss of long noncoding RNA PRAL in hepatocellular carcinoma. Hepatology 2016;63:850-63. [Crossref] [PubMed]
  6. Bertone P, Stolc V, Royce TE, et al. Global identification of human transcribed sequences with genome tiling arrays. Science 2004;306:2242-6. [Crossref] [PubMed]
  7. Anastasiadou E, Jacob LS, Slack FJ. Non-coding RNA networks in cancer. Nat Rev Cancer 2018;18:5-18. [Crossref] [PubMed]
  8. Cech TR, Steitz JA. The noncoding RNA revolution-trashing old rules to forge new ones. Cell 2014;157:77-94. [Crossref] [PubMed]
  9. Du WW, Yang W, Liu E, et al. Foxo3 circular RNA retards cell cycle progression via forming ternary complexes with p21 and CDK2. Nucleic Acids Res 2016;44:2846-58. [Crossref] [PubMed]
  10. Chen J, Li Y, Zheng Q, et al. Circular RNA profile identifies circPVT1 as a proliferative factor and prognostic marker in gastric cancer. Cancer Lett 2017;388:208-19. [Crossref] [PubMed]
  11. Han D, Li J, Wang H, et al. Circular RNA circMTO1 acts as the sponge of microRNA-9 to suppress hepatocellular carcinoma progression. Hepatology 2017;66:1151-64. [Crossref] [PubMed]
  12. Tang L, Chen HY, Hao NB, et al. microRNA inhibitors: Natural and artificial sequestration of microRNA. Cancer Lett 2017;407:139-47. [Crossref] [PubMed]
  13. Hansen TB, Jensen TI, Clausen BH, et al. Natural RNA circles function as efficient microRNA sponges. Nature 2013;495:384-8. [Crossref] [PubMed]
  14. Wang K, Gan TY, Li N, et al. Circular RNA mediates cardiomyocyte death via miRNA-dependent upregulation of MTP18 expression. Cell Death Differ 2017;24:1111-20. [Crossref] [PubMed]
  15. Yu CY, Li TC, Wu YY, et al. The circular RNA circBIRC6 participates in the molecular circuitry controlling human pluripotency. Nat Commun 2017;8:1149. [Crossref] [PubMed]
  16. Zheng Q, Bao C, Guo W, et al. Circular RNA profiling reveals an abundant circHIPK3 that regulates cell growth by sponging multiple miRNAs. Nat Commun 2016;7:11215. [Crossref] [PubMed]
  17. Hsiao KY, Lin YC, Gupta SK, et al. Noncoding Effects of Circular RNA CCDC66 Promote Colon Cancer Growth and Metastasis. Cancer Res 2017;77:2339-50. [Crossref] [PubMed]
  18. Qiu M, Xia W, Chen R, et al. The Circular RNA circPRKCI Promotes Tumor Growth in Lung Adenocarcinoma. Cancer Res 2018;78:2839-51. [Crossref] [PubMed]
  19. Network CGAR. Comprehensive molecular profiling of lung adenocarcinoma. Nature 2014;511:543-50. [Crossref] [PubMed]
  20. Justilien V, Walsh MP, Ali SA, et al. The PRKCI and SOX2 oncogenes are coamplified and cooperate to activate Hedgehog signaling in lung squamous cell carcinoma. Cancer Cell 2014;25:139-51. [Crossref] [PubMed]
  21. Zhu X, Wang X, Wei S, et al. hsa_circ_0013958: a circular RNA and potential novel biomarker for lung adenocarcinoma. FEBS J 2017;284:2170-82. [Crossref] [PubMed]
  22. Mitxelena J, Apraiz A, Vallejo-Rodríguez J, et al. E2F7 regulates transcription and maturation of multiple microRNAs to restrain cell proliferation. Nucleic Acids Res 2016; [Epub ahead of print]. [Crossref] [PubMed]
  23. Salvatori B, Iosue I, Mangiavacchi A, et al. The microRNA-26a target E2F7 sustains cell proliferation and inhibits monocytic differentiation of acute myeloid leukemia cells. Cell Death Dis 2012;3:e413 [Crossref] [PubMed]
  24. Watanabe T, Marotta M, Suzuki R, et al. Impediment of Replication Forks by Long Non-coding RNA Provokes Chromosomal Rearrangements by Error-Prone Restart. Cell Rep 2017;21:2223-35. [Crossref] [PubMed]
doi: 10.21037/ncri.2018.06.04
Cite this article as: Manguso N, Giuliano AE, Tanaka H. circRNA meets gene amplification. Non-coding RNA Investig 2018;2:38.

Download Citation